average monthly weight loss on tirzepatide causes more than semaglutide Body weight loss with tirzepatide

Cross-trial efficacy comparisons should be interpreted with caution given differences in study design, population, duration and primary endpoints

After seeing Ozempics potential for weight loss, its manufacturer, Novo Nordisk, started a new clinical trial program focused solely on assessing safety and efficacy for weight loss

Next-generation GLP-1 therapies: A step closer to integrated metabolic care These results suggest a promising step forward for triple-agonists in diabetes and weight-loss management and highlight the importance of assessing cardiometabolic health holistically

Features Recurring stories and special news packages from C&EN

This part is simple